High Prevalence of Antiretroviral Drug Resistance among HIV-1-Untreated Patients in Guinea-Conakry and in Niger

Abstract

Background

The aim of the study was to assess the prevalence of antiretroviral drug resistance mutations in HIV-1 from recently diagnosed and untreated patients living in Conakry, Guinea-Conakry and in Niamey, Niger.

Methods

The study was performed in two countries of Western Africa – Guinea-Conakry and Niger – using the same survey method in both sites. All newly HIV-1 diagnosed patients, naive of antiretroviral drugs, were consecutively included during September 2009 in each of the two sites. Protease and reverse transcriptase sequencing was performed using the ANRS procedures. Drug resistance mutations were identified according to the 2009 update surveillance drug resistance mutations.

Results

In Conakry, 99 patients were included, most of whom (89%) were infected with CRF02_AG recombinant virus. Resistance analysis among the 93 samples showed that ≥1 drug resistance mutation was observed in 8 samples, leading to a prevalence of primary resistance of 8.6% (95% CI 2.91–14.29%). In Niamey, 96 patients were included; a high diversity in HIV-1 subtypes was observed with 47 (51%) patients infected with CRF02_AG. Resistance analysis performed among the 92 samples with successful genotypic resistance test showed that ≥1 drug resistance mutation was observed in 6 samples, leading to a prevalence of primary resistance of 6.5% (95% CI 1.50–11.50%).

Conclusions

We reported the first antiretroviral drug resistance survey studies in antiretroviral-naive patients living in Guinea-Conakry and in Niger. The prevalence of resistance was between 6% and 9% in both sites, which is higher than most of the other countries from Western Africa region.

References

Tebit

D.M.

, Sangaré

, Tiba

Analysis of the diversity of the HIV-1 pol gene and drug resistance associated changes among drug-naive patients in Burkina Faso. J Med Virol 2009; 81: 1691–1701.

Toni

, Masquelier

, Minga

HIV-1 antiretroviral drug resistance in recently infected patients in Abidjan, Côte d'Ivoire: a 4-year survey, 2002–2006. AIDS Res Hum Retroviruses 2007; 23: 1155–1160.

Derache

, Traore

, Koita

Genetic diversity and drug resistance mutations in HIV type 1 from untreated patients in Bamako, Mali. Antivir Ther 2007; 12: 123–129.

Abreu

C.M.

, Brindeiro

P.A.

, Martins

A.N.

Genotypic and phenotypic characterization of human immunodeficiency virus type 1 isolates circulating in pregnant women from Mozambique. Arch Virol 2008; 153: 2013–2017.

Eshleman

S.H.

, Laeyendecker

, Parkin

Antiretroviral drug susceptibility among drug-naive adults with recent HIV infection in Rakai, Uganda. AIDS 2009; 23: 845–852.

Galluzzo

C.M.

, Germinario

E.A.

, Bassani

Antiretroviral resistance mutations in untreated pregnant women with HIV infection in Uganda and Rwanda. AIDS Res Hum Retroviruses 2007; 23: 1449–1451.

Hamers

R.L.

, Siwale

, Wallis

C.L.

HIV-1 drug resistance mutations are present in six percent of persons initiating antiretroviral therapy in Lusaka, Zambia. J Acquir Immune Defic Syndr 2010; 55: 95–101.

Hamers

R.L.

, Derdelinckx

, van Vugt

The status of HIV-1 resistance to antiretroviral drugs in sub-Saharan Africa. Antivir Ther 2008; 13: 625–639.

Sendagire

, Easterbrook

P.J.

, Nankya

, Arts

, Thomas

, Reynolds

S.J.

The challenge of HIV-1 antiretroviral resistance in Africa in the era of HAART. AIDS Rev 2009; 11: 59–70.

10.

Flys

T.S.

, Chen

, Jones

D.C.

Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. J Acquir Immune Defic Syndr 2006; 42: 610–613.

11.

Eshleman

S.H.

, Hoover

D.R.

, Chen

Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS 2005; 19: 2167–2169.

12.

WHO, UNAIDS, UNICEF. Epidemiological fact sheet on HIV and AIDS: core data on epidemiology and response. Guinea: 2008 update. (Updated 18 February 2009. Accessed 31 July 2010.) Available from http://apps.who.int/globalatlas/predefinedReports/EFS2008/full/EFS2008_GN.pdf.

13.

WHO, UNAIDS, UNICEF. Epidemiological fact sheet on HIV and AIDS: core data on epidemiology and response. Niger: 2008 update. (Updated 18 February 2009. Accessed 31 July 2010.) Available from http://apps.who.int/globalatlas/predefinedReports/EFS2008/full/EFS2008_NE.pdf.

14.

HIV French Resistance. HIV-1 genotypic drug resistance interpretation's algorithms. (Updated 15 September 2010. Accessed 31 July 2010.) Available from http://www.hivfrenchresistance.org/.

15.

Bennett

D.E.

, Camacho

R.J.

, Otelea

Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS ONE 2009; 4: e4724.

16.

Los Alamos National Lab. LANL HIV databases. (Updated 16 August 2010. Accessed 1 September 2010.) Available from http://hiv-web.lanl.gov.

17.

Jung

B.H.

, Rezk

N.L.

, Bridges

A.S.

, Corbett

A.H.

, Kashuba

A.D.

Simultaneous determination of 17 antiretroviral drugs in human plasma for quantitative analysis with liquid chromatography-tandem mass spectrometry. Biomed Chromatogr 2007; 21: 1095–1104.

18.

Paredes

, Lalama

C.M.

, Ribaudo

H.J.

Pre-existing minority drug-resistant HIV-1 variants, adherence, and risk of antiretroviral treatment failure. J Infect Dis 2010; 201: 662–671.

19.

Johnson

J.A.

, Li

J.F.

, Wei

Minority HIV-1 drug resistance mutations are present in antiretroviral treatment-naive populations and associate with reduced treatment efficacy. PLoS Med 2008; 5: e158.

20.

Bennett

D.E.

, Myatt

, Bertagnolio

, Sutherland

, Gilks

C F.

Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment. Antivir Ther 2008; 13 Suppl 2: 25–36.